A549 and H358 cell lines, which harbor KRAS G12S and G12C point mutations respectively, were used with normal lung fibroblast CCD19-Lu and a BRAF mutation lung cancer cell line, H1395, providing KRAS wild-type (WT) controls. Here, KRAS is linked to lung carcinoma.